EPHA2 and neoplasm: The authors used the CNS- or tumor-specific antigens myelin oligodendrocyte glycoprotein (MOG) or EGFRvIII, respectively, as activating signal for the expression of anti-EphA2 or anti-IL13Ra2 CARs.